ciprofloxacin has been researched along with Cystitis in 47 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective, randomized study of Canephron N and ciprofloxacin for treating mild forms of acute uncomplicated cystitis (ACSS score less or equal 10) comprising 160 women aged 18-55 years was conducted from 2015 to 2017." | 9.27 | [Comparative assessment of Canephron N and ciprofloxacin as monotherapy of acute uncomplicated cystitis in women]. ( Bunova, NE; Davidov, MI, 2018) |
| "Among women with uncomplicated cystitis, a 3-day regimen of cefpodoxime compared with ciprofloxacin did not meet criteria for noninferiority for achieving clinical cure." | 9.16 | Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. ( Hooton, TM; Roberts, PL; Stapleton, AE, 2012) |
| "Furagin (a nitrofurantoin analogue) has the same efficacy in treating acute cystitis as ciprofloxacin, however the duration of therapy is longer." | 9.13 | Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. ( Borkowski, A; Dybowski, B; Gromadzka-Ostrowska, J; Jabłońska, O; Radziszewski, P, 2008) |
| "To compare the efficacy of a 3-day regimen of amoxicillin-clavulanate to that of a 3-day regimen of ciprofloxacin in the treatment of acute cystitis in women." | 9.11 | Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. ( Gupta, K; Hooton, TM; Roberts, PL; Scholes, D; Stamm, WE; Stapleton, AE, 2005) |
| "A multicentric double-blind double-placebo randomized trial was conducted to compare the effectiveness and safety of ciprofloxacin versus pefloxacin given in a single oral dose in female out-patients with acute cystitis." | 9.08 | [Efficacy of single dose of ciprofloxacin and pefloxacin in the treatment of female acute cystitis]. ( Guibert, J, 1995) |
| "To clarify the characteristics of the virulence factors (VFs) of ciprofloxacin resistant Escherichia coli (CFRE) with acute uncomplicated cystitis (AUC), we determined the VFs and the phylogenetic background of all 54 CFRE strains and the 55 randomly selected ciprofloxacin sensitive E." | 7.76 | Virulence characteristics and phylogenetic background of ciprofloxacin resistant Escherichia coli in the urine samples from Korean women with acute uncomplicated cystitis. ( Cho, IR; Cho, YH; Kim, CS; Kim, ME; Lee, G, 2010) |
| " We also investigated the efficacy and safety profile of once-daily ciprofloxacin in a 500-mg PO extended-release formulation for 3 days to treat acute cystitis." | 7.72 | A 'gap' between physician and patient assessment of symptom severity in acute cystitis?: a multicenter trial of women treated with extended-release ciprofloxacin. ( Brigio, FD; Colgan, R; Keating, KN; Perfetto, EM; Sirotenko, GA; Song, J; Tucker, MK; Wilson, K, 2004) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 7.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "Oral doses of norfloxacin (80 mg/kg of body weight per day) and ciprofloxacin (25 and 80 mg/kg/day) and intramuscular doses of teicoplanin (5 mg/kg/day), all administered once a day for 10 days, were evaluated as a means of preventing encrusted cystitis caused by Corynebacterium group D2." | 7.68 | Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. ( Avilés, P; Castilla, C; Rodriguez-Tudela, JL; Soriano, F, 1991) |
| " Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT." | 5.37 | Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011) |
| "A prospective, randomized study of Canephron N and ciprofloxacin for treating mild forms of acute uncomplicated cystitis (ACSS score less or equal 10) comprising 160 women aged 18-55 years was conducted from 2015 to 2017." | 5.27 | [Comparative assessment of Canephron N and ciprofloxacin as monotherapy of acute uncomplicated cystitis in women]. ( Bunova, NE; Davidov, MI, 2018) |
| "Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture were included in a randomized, double-blind clinical trial." | 5.22 | A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. ( Allegrini, A; García-Larrosa, A; Pavone, D; Salvatorelli, N, 2016) |
| "Among women with uncomplicated cystitis, a 3-day regimen of cefpodoxime compared with ciprofloxacin did not meet criteria for noninferiority for achieving clinical cure." | 5.16 | Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. ( Hooton, TM; Roberts, PL; Stapleton, AE, 2012) |
| "Furagin (a nitrofurantoin analogue) has the same efficacy in treating acute cystitis as ciprofloxacin, however the duration of therapy is longer." | 5.13 | Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. ( Borkowski, A; Dybowski, B; Gromadzka-Ostrowska, J; Jabłońska, O; Radziszewski, P, 2008) |
| "To compare the efficacy of a 3-day regimen of amoxicillin-clavulanate to that of a 3-day regimen of ciprofloxacin in the treatment of acute cystitis in women." | 5.11 | Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. ( Gupta, K; Hooton, TM; Roberts, PL; Scholes, D; Stamm, WE; Stapleton, AE, 2005) |
| "Pre-menopausal women presenting with acute uncomplicated cystitis were randomized to treatment with 3 days of ciprofloxacin, 7 days of nitrofurantoin, or a single dose of fosfomycin." | 5.11 | Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. ( Gupta, K; Hooton, TM; Stamm, WE, 2005) |
| "The study was undertaken to compare the safety and efficacy of twice-daily ciprofloxacin for 3 days with standard 7 day therapy with either co-trimoxazole or nitrofurantoin in the treatment of women with acute, uncomplicated urinary tract infections (UTI)." | 5.09 | A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. ( Briefer, C; Echols, RM; Iravani, A; Klimberg, I; Kowalsky, SF; Munera, C, 1999) |
| "A multicentric double-blind double-placebo randomized trial was conducted to compare the effectiveness and safety of ciprofloxacin versus pefloxacin given in a single oral dose in female out-patients with acute cystitis." | 5.08 | [Efficacy of single dose of ciprofloxacin and pefloxacin in the treatment of female acute cystitis]. ( Guibert, J, 1995) |
| "Pharmacodynamic profiling of oral ciprofloxacin dosing for urinary tract infections caused by ceftriaxone-resistant Escherichia coli isolates with ciprofloxacin MIC ≥ 0." | 4.31 | Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model. ( Abbott, IJ; Cottingham, H; Macesic, N; Meletiadis, J; Peleg, AY; Roberts, JA; van Gorp, E; Wallis, SC, 2023) |
| "The purpose of this study was to investigate the effect of ciprofloxacin treatment on quality of life and symptom improvement in patients with simple cystitis." | 3.81 | Quality of life and changes in symptom relief in patients with acute uncomplicated cystitis treated with antibiotics: a prospective, open-label, multicenter, observational study. ( Bae, JH; Choi, H; Kim, YH, 2015) |
| "Fosfomycin is recommended as first-line treatment for acute uncomplicated cystitis in women." | 3.81 | Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. ( Eliopoulos, GM; Hirsch, EB; Kim, Y; Kirby, JE; McCoy, C; Raux, BR; Wright, SB; Zucchi, PC, 2015) |
| "According to Norwegian guidelines for antibiotic use in primary care, ciprofloxacin is reserved for complicated urinary tract infections (UTI)." | 3.80 | A simple intervention to reduce inappropriate ciprofloxacin prescribing in the emergency department. ( Berild, D; Fagan, M; Lindbæk, M; Reiso, H, 2014) |
| "To clarify the characteristics of the virulence factors (VFs) of ciprofloxacin resistant Escherichia coli (CFRE) with acute uncomplicated cystitis (AUC), we determined the VFs and the phylogenetic background of all 54 CFRE strains and the 55 randomly selected ciprofloxacin sensitive E." | 3.76 | Virulence characteristics and phylogenetic background of ciprofloxacin resistant Escherichia coli in the urine samples from Korean women with acute uncomplicated cystitis. ( Cho, IR; Cho, YH; Kim, CS; Kim, ME; Lee, G, 2010) |
| "We investigated the risk factors for resistance to ciprofloxacin, cefazolin, ampicillin and co-trimoxazole in Escherichia coli isolates from urine of Korean female patients with acute uncomplicated cystitis (AUC)." | 3.76 | Risk factors for antimicrobial resistance among the Escherichia coli strains isolated from Korean patients with acute uncomplicated cystitis: a prospective and nationwide study. ( Cho, YH; Lee, G; Lee, SD; Shim, BS, 2010) |
| " We also investigated the efficacy and safety profile of once-daily ciprofloxacin in a 500-mg PO extended-release formulation for 3 days to treat acute cystitis." | 3.72 | A 'gap' between physician and patient assessment of symptom severity in acute cystitis?: a multicenter trial of women treated with extended-release ciprofloxacin. ( Brigio, FD; Colgan, R; Keating, KN; Perfetto, EM; Sirotenko, GA; Song, J; Tucker, MK; Wilson, K, 2004) |
| "The prevalence of hemolysin, type 1 fimbriae, P fimbriae, cytotoxic necrotizing factor-1 (CNF-1), aerobactin, and autotransporter toxin (sat) was analyzed by polymerase chain reaction and phenotypic assays of 42 epidemiologically unrelated Escherichia coli strains causing acute pyelonephritis in women (21 nalidixic acid-susceptible and 21 nalidixic acid-resistant strains) and 58 E." | 3.71 | Are quinolone-resistant uropathogenic Escherichia coli less virulent? ( Barranco, M; Horcajada, JP; Mensa, J; Moreno, A; Ruiz, J; Simon, K; Velasco, M; Vila, J, 2002) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 3.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "Oral doses of norfloxacin (80 mg/kg of body weight per day) and ciprofloxacin (25 and 80 mg/kg/day) and intramuscular doses of teicoplanin (5 mg/kg/day), all administered once a day for 10 days, were evaluated as a means of preventing encrusted cystitis caused by Corynebacterium group D2." | 3.68 | Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. ( Avilés, P; Castilla, C; Rodriguez-Tudela, JL; Soriano, F, 1991) |
| "To evaluate QOL in women treated for acute cystitis, and describe the relationship between QOL, clinical outcome and adverse events of each of the interventions used in the study." | 2.71 | Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. ( Bergus, GR; Ernst, EJ; Ernst, ME; Hoehns, JD, 2005) |
| "Uncomplicated acute cystitis is one of the most common bacterial infections in adults." | 2.43 | Quinolones for uncomplicated acute cystitis in women. ( Andreeva, I; Rafalsky, V; Rjabkova, E, 2006) |
| "Emphysematous cystitis is a very rare complicated urinary tract infection characterized by air in the bladder wall." | 1.42 | Emphysematous cystitis presenting as severe confusion and abdominal pain: two case reports. ( De Coninck, V; Michielsen, D, 2015) |
| " Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT." | 1.37 | Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (12.77) | 18.7374 |
| 1990's | 6 (12.77) | 18.2507 |
| 2000's | 16 (34.04) | 29.6817 |
| 2010's | 16 (34.04) | 24.3611 |
| 2020's | 3 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Abbott, IJ | 2 |
| van Gorp, E | 2 |
| Cottingham, H | 2 |
| Macesic, N | 2 |
| Wallis, SC | 2 |
| Roberts, JA | 2 |
| Meletiadis, J | 2 |
| Peleg, AY | 2 |
| Guo, RF | 1 |
| Nguyen, DL | 1 |
| Park, S | 1 |
| Nguyen, K | 1 |
| Ko, S | 1 |
| Chiu, VY | 1 |
| Dickter, J | 1 |
| Becker, D | 1 |
| Cho, P | 1 |
| Megna, M | 1 |
| Camela, E | 1 |
| Ocampo Garza, SS | 1 |
| Marino, V | 1 |
| Costanzo, L | 1 |
| Scalvenzi, M | 1 |
| Fabbrocini, G | 1 |
| Gallo, L | 1 |
| Davidov, MI | 1 |
| Bunova, NE | 1 |
| Panchev, P | 1 |
| Slavov, Ch | 1 |
| Mladenov, D | 1 |
| Georgiev, M | 1 |
| Yanev, K | 1 |
| Paskalev, E | 1 |
| Simeonov, P | 1 |
| Gerassi, R | 1 |
| Bogov, B | 1 |
| Saltirov, I | 1 |
| Fagan, M | 1 |
| Lindbæk, M | 1 |
| Reiso, H | 1 |
| Berild, D | 1 |
| Can, F | 1 |
| Azap, OK | 1 |
| Seref, C | 1 |
| Ispir, P | 1 |
| Arslan, H | 1 |
| Ergonul, O | 1 |
| Choi, H | 1 |
| Kim, YH | 1 |
| Bae, JH | 1 |
| De Coninck, V | 1 |
| Michielsen, D | 1 |
| Hirsch, EB | 1 |
| Raux, BR | 1 |
| Zucchi, PC | 1 |
| Kim, Y | 1 |
| McCoy, C | 1 |
| Kirby, JE | 1 |
| Wright, SB | 1 |
| Eliopoulos, GM | 1 |
| Kim, HY | 1 |
| Lee, SJ | 1 |
| Lee, DS | 1 |
| Yoo, JM | 1 |
| Choe, HS | 1 |
| Wegner, J | 1 |
| Salvatorelli, N | 1 |
| García-Larrosa, A | 1 |
| Allegrini, A | 1 |
| Pavone, D | 1 |
| Jun, JB | 1 |
| Choi, Y | 1 |
| Kim, H | 1 |
| Lee, SH | 1 |
| Jeong, J | 1 |
| Jung, J | 1 |
| Cagnacci, S | 1 |
| Gualco, L | 1 |
| Debbia, E | 1 |
| Schito, GC | 1 |
| Marchese, A | 1 |
| Hoskins, R | 1 |
| Wojnicz, D | 2 |
| Cisowska, A | 1 |
| Suárez Laurés, A | 1 |
| Pobes, A | 1 |
| Pérez-Carral, JR | 1 |
| Quiñones Ortiz, L | 1 |
| Tucker, MK | 1 |
| Brigio, FD | 1 |
| Sirotenko, GA | 1 |
| Keating, KN | 1 |
| Perfetto, EM | 1 |
| Wilson, K | 1 |
| Song, J | 1 |
| Colgan, R | 1 |
| Kim, CS | 1 |
| Kim, ME | 1 |
| Cho, YH | 2 |
| Cho, IR | 1 |
| Lee, G | 2 |
| Shim, BS | 1 |
| Lee, SD | 1 |
| Miller, AN | 1 |
| Glode, A | 1 |
| Hogan, KR | 1 |
| Schaub, C | 1 |
| Kramer, C | 1 |
| Stuart, RK | 1 |
| Costa, LJ | 1 |
| Jichlinski, P | 1 |
| Hooton, TM | 3 |
| Roberts, PL | 2 |
| Stapleton, AE | 2 |
| Vila, J | 1 |
| Simon, K | 1 |
| Ruiz, J | 1 |
| Horcajada, JP | 1 |
| Velasco, M | 1 |
| Barranco, M | 1 |
| Moreno, A | 1 |
| Mensa, J | 1 |
| Millán Rodríguez, F | 1 |
| Rousaud Barón, F | 1 |
| Rousaud Barón, A | 1 |
| Scholes, D | 1 |
| Gupta, K | 2 |
| Stamm, WE | 2 |
| Ernst, EJ | 1 |
| Ernst, ME | 1 |
| Hoehns, JD | 1 |
| Bergus, GR | 1 |
| Rafalsky, V | 1 |
| Andreeva, I | 1 |
| Rjabkova, E | 1 |
| Jankowski, S | 1 |
| Dybowski, B | 1 |
| Jabłońska, O | 1 |
| Radziszewski, P | 1 |
| Gromadzka-Ostrowska, J | 1 |
| Borkowski, A | 1 |
| Lin, CJ | 1 |
| Chen, HH | 1 |
| Chen, YC | 1 |
| Wu, CJ | 1 |
| Greenwood, D | 2 |
| Baxter, S | 1 |
| Cowlishaw, A | 1 |
| Eley, A | 1 |
| Slater, GJ | 1 |
| Guibert, J | 2 |
| Grekas, D | 1 |
| Thanos, V | 1 |
| Dioudis, C | 1 |
| Alivanis, P | 1 |
| Tourkantonis, A | 1 |
| Loran, OB | 1 |
| Pushkar', DIu | 1 |
| Tevlin, KP | 1 |
| Goto, T | 1 |
| Kitagawa, T | 1 |
| Kawahara, M | 1 |
| Hayami, H | 1 |
| Ohi, Y | 1 |
| Iravani, A | 1 |
| Klimberg, I | 1 |
| Briefer, C | 1 |
| Munera, C | 1 |
| Kowalsky, SF | 1 |
| Echols, RM | 1 |
| Soriano, F | 1 |
| Rodriguez-Tudela, JL | 1 |
| Castilla, C | 1 |
| Avilés, P | 1 |
| Kanematsu, M | 1 |
| Destrée, D | 1 |
| Konopka, C | 1 |
| Acar, J | 1 |
| Van Poppel, H | 1 |
| Wegge, M | 1 |
| Dammekens, H | 1 |
| Chysky, V | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Møller, BR | 1 |
| Kaspersen, P | 1 |
| Mamsen, A | 1 |
| Korsager, B | 1 |
| Quitzau, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Epidemiology of ST131 in Besançon University Hospital[NCT02853708] | 300 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203] | Phase 4 | 200 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Cefpodoxime vs Ciprofloxacin for Acute Cystitis[NCT00194532] | 300 participants (Actual) | Interventional | 2005-06-30 | Completed | |||
| Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infections[NCT00305227] | Phase 2 | 100 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 31 |
| Placebo | 8 |
Clostridium difficile infection at 6 months (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 0 |
Patient death at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 1 |
First BK plasma viral loads (NCT01789203)
Timeframe: 12 months
| Intervention | copies/mL (Median) |
|---|---|
| Ciprofloxacin | 2514 |
| Placebo | 1423 |
kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 25 |
| Placebo | 5 |
Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 3 |
| Placebo | 2 |
Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 17 |
| Placebo | 14 |
Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 15 |
| Placebo | 7 |
Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 35 |
| Placebo | 18 |
Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months
| Intervention | days (Median) |
|---|---|
| Ciprofloxacin | 90 |
| Placebo | 76.5 |
Participants with clinical cure, i.e. free of urinary tract symptoms and requiring no further antibiotic treatment, to assess the efficacy of a 3-day regimen of cefpodoxime compared to ciprofloxacin (NCT00194532)
Timeframe: 28-30 days post therapy
| Intervention | participants (Number) | |
|---|---|---|
| Cure | Not cure | |
| Cefpodoxime | 123 | 27 |
| Ciprofloxacin | 140 | 10 |
Elimination or decrease of causative uropathogen(s) in the mid-stream urine culture at follow-up (NCT00194532)
Timeframe: 1-15 days post therapy
| Intervention | participants (Number) | |
|---|---|---|
| Cure | Not cure | |
| Cefpodoxime | 104 | 25 |
| Ciprofloxacin | 123 | 5 |
Recurrent urinary tract infection after initiation of intervention. Culture-confirmed to contain uropathogen. (NCT00305227)
Timeframe: 10 weeks
| Intervention | participants (Number) |
|---|---|
| Lactin-V | 7 |
| Placebo | 13 |
(NCT00305227)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Lactin-V | 4 |
| Placebo | 5 |
1 review available for ciprofloxacin and Cystitis
| Article | Year |
|---|---|
Quinolones for uncomplicated acute cystitis in women.
Topics: Acute Disease; Adult; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis; Female; Fluoroquinolo | 2006 |
12 trials available for ciprofloxacin and Cystitis
| Article | Year |
|---|---|
[Comparative assessment of Canephron N and ciprofloxacin as monotherapy of acute uncomplicated cystitis in women].
Topics: Acute Disease; Adolescent; Adult; Ciprofloxacin; Cystitis; Female; Humans; Middle Aged; Plant Extrac | 2018 |
[A multicenter comparative observation on the effectiveness and the rapidness of the effect of Cystostop Rapid versus antibiotic therapy in patients with uncomplicated cystitis].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Betula; Ciprofloxacin; Cystitis; Female; Humans; Mannose; | 2012 |
A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Capsules; Ciprofloxacin; Cystitis; Double-Blind Method; | 2016 |
Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefpodoxime; Ceftizox | 2012 |
Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cystitis | 2005 |
Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis.
Topics: Acute Disease; Adolescent; Adult; Ciprofloxacin; Cystitis; Drug Resistance, Bacterial; Escherichia c | 2005 |
Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment.
Topics: Acute Disease; Adult; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis; Female; Humans; Middl | 2005 |
Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results.
Topics: Acute Disease; Adult; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis | 2008 |
[Efficacy of single dose of ciprofloxacin and pefloxacin in the treatment of female acute cystitis].
Topics: Acute Disease; Administration, Oral; Adult; Ciprofloxacin; Cystitis; Double-Blind Method; Female; Hu | 1995 |
[Experience with the use of ciprofloxacin in patients with acute uncomplicated cystitis].
Topics: Acute Disease; Adult; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteriuria; Ciprofloxa | 1997 |
Comparative study of single-dose and three-day therapy for acute uncomplicated cystitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Cefpodoxime Proxetil; Ceftizoxime; Ci | 1999 |
A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Age | 1999 |
34 other studies available for ciprofloxacin and Cystitis
| Article | Year |
|---|---|
Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Topics: Anti-Bacterial Agents; Bacteria; Ceftriaxone; Ciprofloxacin; Cystitis; Escherichia coli; Humans; Mic | 2023 |
Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Topics: Anti-Bacterial Agents; Bacteria; Ceftriaxone; Ciprofloxacin; Cystitis; Escherichia coli; Humans; Mic | 2023 |
Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Topics: Anti-Bacterial Agents; Bacteria; Ceftriaxone; Ciprofloxacin; Cystitis; Escherichia coli; Humans; Mic | 2023 |
Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Topics: Anti-Bacterial Agents; Bacteria; Ceftriaxone; Ciprofloxacin; Cystitis; Escherichia coli; Humans; Mic | 2023 |
Practitioner Education and Feedback to Decrease Ciprofloxacin Prescriptions in Patients with Acute Uncomplicated Cystitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Drug Prescriptions; Female; Fo | 2020 |
Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Exanthema; Female; Humans; Psoriasis | 2021 |
A simple intervention to reduce inappropriate ciprofloxacin prescribing in the emergency department.
Topics: Amdinocillin; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Emergency Service, Hospital; Female; H | 2014 |
Emerging Escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections.
Topics: Aged; Anti-Bacterial Agents; Bacterial Typing Techniques; Cefuroxime; Ciprofloxacin; Cohort Studies; | 2015 |
Quality of life and changes in symptom relief in patients with acute uncomplicated cystitis treated with antibiotics: a prospective, open-label, multicenter, observational study.
Topics: Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Female; Humans; Male; Middle Aged; Pros | 2015 |
Emphysematous cystitis presenting as severe confusion and abdominal pain: two case reports.
Topics: Abdominal Pain; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Confusion; Cystitis; | 2015 |
Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.
Topics: Anti-Bacterial Agents; Bacteriuria; Ciprofloxacin; Cystitis; Drug Resistance, Bacterial; Enterobacte | 2015 |
Microbiological Characteristics of Unresolved Acute Uncomplicated Cystitis.
Topics: Acute Disease; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ce | 2016 |
[Cystitis. Ultrasound only in complicated anamnesis].
Topics: Ciprofloxacin; Cystitis; Dose-Response Relationship, Drug; Humans; Medical History Taking; Ultrasono | 2015 |
BK polyomavirus encephalitis in a patient with thrombotic microangiopathy after an allogeneic hematopoietic stem cell transplant.
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Antiviral Agents; BK Virus; Cidofovir; Ciprofloxacin; Cyst | 2016 |
European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis.
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Ciprofloxacin; Cluster A | 2008 |
Ketamine associated cystitis - a case report.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystitis; Cystoscopy; Emergency Treatment; Humans; Keta | 2009 |
Composition of the outer membrane proteins of Escherichia coli strains in relation to serum susceptibility after exposure to subinhibitory concentrations of amikacin and ciprofloxacin.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Child; Ciprofloxacin; Cystitis; | 2009 |
[Pneumaturia and kidney polycystosis in adults].
Topics: Aged; Air; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Cystitis; Emphysema; Esc | 2009 |
A 'gap' between physician and patient assessment of symptom severity in acute cystitis?: a multicenter trial of women treated with extended-release ciprofloxacin.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Ciprofloxac | 2004 |
Virulence characteristics and phylogenetic background of ciprofloxacin resistant Escherichia coli in the urine samples from Korean women with acute uncomplicated cystitis.
Topics: Adolescent; Adult; Aged; Asian People; Bacterial Typing Techniques; Ciprofloxacin; Cystitis; Drug Re | 2010 |
Risk factors for antimicrobial resistance among the Escherichia coli strains isolated from Korean patients with acute uncomplicated cystitis: a prospective and nationwide study.
Topics: Acute Disease; Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; | 2010 |
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.
Topics: Adult; Aged; Anti-Infective Agents; BK Virus; Ciprofloxacin; Cystitis; Female; Hematologic Neoplasms | 2011 |
[Urology in 2011].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Ag | 2012 |
Are quinolone-resistant uropathogenic Escherichia coli less virulent?
Topics: Anti-Infective Agents; Bacterial Toxins; Ciprofloxacin; Cystitis; Cytotoxins; Drug Resistance, Micro | 2002 |
[Pilot study of coadjuvant treatment of recurrent cystitis in women by means of AM3 (Immnoferon)].
Topics: Adjuvants, Immunologic; Amoxicillin; Calcium Phosphates; Ciprofloxacin; Clavulanic Acid; Cystitis; D | 2003 |
Cipro bests Augmentin in bladder infection treatment.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Cystitis; Femal | 2005 |
Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Adhesion; Ciprofloxacin; Cystitis; | 2007 |
Emphysematous cystitis in a asymptomatic haemodialysis patient.
Topics: Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Cystitis; Emphysema; Female; Humans; Incidental F | 2008 |
Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis; Dose-Response Relationship, Drug; Drug Resi | 1984 |
Treatment of urinary tract infections with ciprofloxacin after renal transplantation.
Topics: Administration, Oral; Adult; Bacterial Infections; Bacteriuria; Ciprofloxacin; Cystitis; Female; Hum | 1993 |
Effectiveness of 3 vs. 7 day therapy cited.
Topics: Anti-Infective Agents; Ciprofloxacin; Cystitis; Drug Administration Schedule; Female; Humans; Norflo | 2001 |
Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium Infections; Cystitis; Female; Glycope | 1991 |
Studies on the emergence of resistance to lomefloxacin in vitro.
Topics: Anti-Infective Agents; Ciprofloxacin; Cystitis; Drug Resistance, Microbial; Escherichia coli; Fluoro | 1989 |
Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Drug | 1986 |
Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.
Topics: Anti-Infective Agents; Catheters, Indwelling; Ciprofloxacin; Cystitis; Enterobacteriaceae Infections | 1986 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
Fleroxacin in the treatment of uncomplicated acute cystitis in women.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Cystitis; Female; Fleroxacin; Follow-Up | 1988 |